Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-10-056700
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-11-23 21:58:31
Reporting Period:
2010-11-19
Filing Date:
2010-11-23
Accepted Time:
2010-11-23 21:58:31
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
876343 Biotime Inc BTX Biological Products, (No Disgnostic Substances) (2836) 943127919
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1054745 Judith Segall 1301 Harbor Bay Parkway
Alameda CA 94502
Vice President & Secretary Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares, No Par Value Disposition 2010-11-19 7,600 $7.47 539,943 No 4 S Direct
Common Shares, No Par Value Disposition 2010-11-22 17,400 $7.52 522,543 No 4 S Direct
Common Shares, No Par Value Disposition 2010-11-23 2,128 $7.70 520,415 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Shares Option to Purchase Common Shares $0.32 2006-11-24 2011-11-23 80,000 80,000 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2011-11-23 80,000 80,000 Direct
Footnotes
  1. The price of $7.4730 per share represents a weighted average of sales prices ranging from $7.45 to $7.4950 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
  2. Includes 23,750 shares acquired through a warrant exercise at $1.818 per share on August 18, 2010; 21,586 shares acquired through a warrant exercise at $2.00 per share on November 1, 2010; and 125,000 shares acquired through an option exercise at $2.00 per share on November 5, 2010. Does not include shares that may be acquired upon the exercise of certain stock options.
  3. The price of $7.5223 per share represents a weighted average of sales prices ranging from $7.4592 to $7.57 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.
  4. The price of $7.6976 per share represents a weighted average of sales prices ranging from $7.68 to $7.72 per share. The reporting person undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.